ELV stock sentiment todayElevance Health Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 78% confidence.
Last updated · cached analysis, refreshes periodically
ELV
Elevance Health IncElevance remains a high-quality defensive play with strong free cash flow, but near-term headwinds in Medicaid re-determinations and Star Ratings create a valuation ceiling.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ELV. Not financial advice.
Price · last 12 months
Gossip
The market is wrestling with a 'value trap' vs. 'undervalued gem' narrative. While analysts highlight a 10-37% upside based on historical multiples, recent price action shows skepticism following revenue beats that were overshadowed by rising medical loss ratios (MLR).
- ·Perceived undervaluation despite long-term price appreciation
- ·Concerns over Medicaid membership attrition
- ·Executive stock withholding for tax liabilities (insider activity monitoring)
- ·Mixed reactions to full-year guidance raises
Financial
ELV maintains a robust balance sheet characterized by aggressive share buybacks and consistent dividend growth. However, margins are under pressure due to higher-than-expected utilization rates in government-sponsored plans.
- ·Forward P/E ratio approximately 10-11x, below 5-year average
- ·Consistently high Return on Equity (ROE) above 15%
- ·Solid mid-single digit revenue growth driven by Carelon (health services wing)
- ·Debt-to-capital ratio remains within manageable management targets
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·Insiders bought a net $542K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Medicare Advantage Star Rating downgrades impacting future bonus payments
- ·Rising Medical Loss Ratio (MLR) as post-pandemic healthcare utilization spikes
- ·Regulatory pressure on Pharmacy Benefit Management (PBM) pricing structures
Peer temperature
How direct competitors stack up against ELV right now.
- HOTUNHUnitedHealth Group
HOTTER — larger scale and superior diversification through Optum provide higher margins and a more resilient moat against regulatory shifts.
See full analysis → - COLDHUMHumana Inc.
COLDER — significantly higher exposure to Medicare Advantage headwinds and recent earnings misses make its recovery path more volatile than ELV.
See full analysis → - COLDCVSCVS Health
COLDER — struggling with heavy debt loads and complex integration of Aetna and Oak Street Health compared to ELV's cleaner operational focus.
See full analysis →
- ELV+4.2%
- UNH-3.8%
- HUM+10.4%
- CVS-2.4%
Analyst price target
Consensus average of 18 analysts · median 460.00
Source: StockAnalysis.com · updated 2026-09-04
Recent headlines
- Yahoo FinanceElevance Health (ELV) Stock Still Looks Undervalued Despite Its 37% Run
- tradingview.com2 Reasons to Watch ELV and 1 to Stay Cautious
- StockStory2 Reasons to Watch ELV and 1 to Stay Cautious
- simplywall.stElevance Health (ELV) Stock Stays Undervalued Despite Its 37% Run
- DirectorsTalk InterviewsElevance Health, Inc. (ELV) Stock Analysis: Evaluating A 10% Upside Potential
- Stock TitanElevance Health (NYSE: ELV) withholds 349 shares to cover EVP tax liability
AI-generated analysis for informational purposes only. Not financial advice.